Aldeyra Therapeutics (ALDX) Revenue & Revenue Breakdown
Aldeyra Therapeutics Revenue Highlights
00
Aldeyra Therapeutics Revenue by Period
Aldeyra Therapeutics Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2019-12-31 | - | 100.00% |
2018-12-31 | - | 100.00% |
2017-12-31 | - | 100.00% |
2016-12-31 | - | 100.00% |
2015-12-31 | - | 100.00% |
2014-12-31 | - | 100.00% |
2013-12-31 | - | 100.00% |
2012-12-31 | - | 100.00% |
2011-12-31 | - | - |
Aldeyra Therapeutics Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-09-30 | - | 100.00% |
2024-06-30 | - | 100.00% |
2024-03-31 | - | -100.00% |
2023-12-31 | $392.62K | 100.00% |
2023-09-30 | - | 100.00% |
2023-06-30 | - | 100.00% |
2023-03-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2022-09-30 | - | 100.00% |
2022-06-30 | - | 100.00% |
2022-03-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2021-09-30 | - | 100.00% |
2021-06-30 | - | 100.00% |
2021-03-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2020-09-30 | - | 100.00% |
2020-06-30 | - | 100.00% |
2020-03-31 | - | 100.00% |
2019-12-31 | - | 100.00% |
2019-09-30 | - | 100.00% |
2019-06-30 | - | 100.00% |
2019-03-31 | - | 100.00% |
2018-12-31 | - | 100.00% |
2018-09-30 | - | 100.00% |
2018-06-30 | - | -100.00% |
2018-03-31 | $8.30M | -100.00% |
2017-12-31 | $24.12T | 100.00% |
2017-09-30 | - | 100.00% |
2017-06-30 | - | -100.00% |
2017-03-31 | $4.01M | -75.10% |
2016-12-31 | $16.11M | 100.00% |
2016-09-30 | - | 100.00% |
2016-06-30 | - | 100.00% |
2016-03-31 | - | 100.00% |
2015-12-31 | - | 100.00% |
2015-09-30 | - | 100.00% |
2015-06-30 | - | 100.00% |
2015-03-31 | - | 100.00% |
2014-12-31 | - | 100.00% |
2014-09-30 | - | 100.00% |
2014-06-30 | - | 100.00% |
2014-03-31 | - | 100.00% |
2013-12-31 | - | 100.00% |
2013-09-30 | - | 100.00% |
2013-06-30 | - | 100.00% |
2013-03-31 | - | 100.00% |
2012-12-31 | - | - |
Aldeyra Therapeutics Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
BPMC | Blueprint Medicines | $249.38M | $128.18M |
TVTX | Travere Therapeutics | $145.24M | $62.90M |
MCRB | Seres Therapeutics | $126.33M | - |
ARDX | Ardelyx | $124.46M | $98.24M |
ETON | Eton Pharmaceuticals | $31.64M | $10.32M |
HOOK | HOOKIPA Pharma | $20.13M | - |
TARS | Tarsus Pharmaceuticals | $17.45M | $48.12M |
BLRX | BioLineRx | $4.80M | $6.86M |
LYRA | Lyra Therapeutics | $1.56M | $195.00K |
LXRX | Lexicon Pharmaceuticals | $1.20M | $1.74M |
PHAT | Phathom Pharmaceuticals | $682.00K | $16.35M |
IBRX | ImmunityBio | $622.00K | $1.05M |
VRDN | Viridian Therapeutics | $314.00K | $86.00K |
CGEM | Cullinan Oncology | - | - |
GPCR | Structure Therapeutics | - | - |
XFOR | X4 Pharmaceuticals | - | $560.00K |
ALDX | Aldeyra Therapeutics | - | - |
DAWN | Day One Biopharmaceuticals | - | $20.07M |
INZY | Inozyme Pharma | - | - |
TERN | Terns Pharmaceuticals | - | - |
ETNB | 89bio | - | - |